Ascentage Pharma to Present 17 Clinical Advances at EHA2026 Congress
AAPG is trading near its 52-week low of $19.11 (12% above the low) on elevated volume (3.8× avg).
Summary
Ascentage Pharma announced it will present 17 clinical advances for its core drug candidates, Olverembatinib and Lisaftoclax, at the upcoming European Hematology Association Congress.
Key Events · Product Development and Regulatory · AAPG
-
Major Clinical Data Presentation
Ascentage Pharma will present 17 clinical advances, including 8 poster presentations, at the 31st European Hematology Association (EHA2026) Congress from June 11-14, 2026.
-
Key Drug Candidates Featured
The presentations will feature data from ongoing clinical studies for Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor.
-
Updated Efficacy and Phase 3 Results
Abstracts include updated efficacy and safety data for Olverembatinib in chronic myeloid leukemia (CML), efficacy in CML with prior resistance, and updated results from the global registrational Phase 3 POLARIS-1 study for Olverembatinib in newly diagnosed Ph+ acute lymphoblastic leukemia (ALL).
Analysis · AAPG · Life Sciences
Ascentage Pharma will present 17 clinical advances, including updated efficacy and safety data for its key assets Olverembatinib and Lisaftoclax, at the European Hematology Association (EHA) Congress in June. This significant number of presentations, particularly the updated Phase 3 results for Olverembatinib and data for Lisaftoclax, provides important updates on the company's pipeline progress and could influence investor sentiment regarding its drug development programs.
At the time of this filing, AAPG was trading at $21.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $19.11 to $48.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.